3 terminated, 2 not yet recruiting, 2 recruiting, 1 active not recruiting. 4 Phase 1, 3 Phase 2, 2 Phase 3, 1 Not applicable.
Follow Liver Cell Carcinoma: new trials by email Literature Review of Liver Cell Carcinoma trials Research Report on Liver Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors SC-CAR.GPC3xIL15.21 CAR T cells - Solid Tumor (Excluding CNS), Hepatocellular Carcinoma | Phase 1 | Not yet recruiting | Seattle Children's Hospital | 21 | 2026-04-01 | 2025-11-04 |
| Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells SC-CAR.GPC3xIL15.21 CAR T cells - Solid Tumor (Excluding CNS), Liver Cell Carcinoma | Phase 1 | Recruiting | Seattle Children's Hospital | 21 | 2025-12-22 | 2026-02-17 |
| Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC LioCyx-M, Lenvatinib - Hepatocellular Carcinoma, Liver Cancer, Adult | Phase 2 | Not yet recruiting | Lion TCR Pte. Ltd. | 55 | 2025-03-01 | 2025-03-10 |
| Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma Tislelizumab - Carcinoma, Hepatocellular, Liver Cell Carcinoma | Phase 2 | Recruiting | Rutgers, The State University of New Jersey | 35 | 2022-07-25 | 2026-01-20 |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors CATCH T cells - Liver Cell Carcinoma, Solid Tumor | Phase 1 | Active not recruiting | Baylor College of Medicine | 12 | 2021-06-17 | 2026-03-06 |
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors Nivolumab, Relatlimab - Hepatocellular Carcinoma, Hepatoma | Phase 2 | Completed | Bristol-Myers Squibb | 266 | 2021-02-04 | 2026-01-08 |
| HepATocellular Cancer Hcv Therapy Study Elbasvir / Grazoprevir Oral Tablet - Hepatocellular Carcinoma, Hepatoma | Phase 3 | Withdrawn | Bayside Health | 2019-09-01 | 2020-09-14 | |
| TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma Transarterial embolization, Microwave Ablation - Hepatocellular Carcinoma, Hepatoma | Not applicable | Terminated | Wake Forest University Health Sciences | 8 | 2016-03-01 | 2022-04-22 |
| A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma DEB-TACE, Sorafenib - Hepatocellular Carcinoma, Hepatoma | Phase 3 | Terminated | Boston Scientific Corporation | 2 | 2015-11-01 | 2021-02-12 |
| Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost - Hepatocellular Carcinoma, Hepatoma | Phase 1 | Terminated | Lisa H. Butterfield, Ph.D. | 2 | 2009-06-01 | 2015-12-03 |
Carcinoma, Hepatocellular (10) · Liver Neoplasms (5) · Endodermal Sinus Tumor (3) · Liposarcoma (3) · Rhabdomyosarcoma (3) · Rhabdoid Tumor (2) · Wilms Tumor (2) · Hepatitis B (1) · Hepatitis C (1) · Hepatoblastoma (1)
Adenocarcinoma (10) · Carcinoma (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Liver Diseases (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Neoplasms, Glandular and Epithelial (10) · Liver Neoplasms (5) · Mesonephroma (3) · Myosarcoma (3) · Neoplasms, Adipose Tissue (3) · Neoplasms, Connective and Soft Tissue (3) · Neoplasms, Germ Cell and Embryonal (3)
Nivolumab (1) · Sorafenib (1) · elbasvir-grazoprevir drug combination (1) · lenvatinib (1) · relatlimab (1) · tislelizumab (1)
Seattle Children's Hospital (2) · Baylor College of Medicine (1) · Bayside Health (1) · Boston Scientific Corporation (1) · Bristol-Myers Squibb (1) · Lion TCR Pte. Ltd. (1) · Lisa H. Butterfield, Ph.D. (1) · Rutgers, The State University of New Jersey (1) · Wake Forest University Health Sciences (1)
United States (7) · Argentina (1) · Brazil (1) · Chile (1) · China (1) · Czechia (1) · France (1) · Hong Kong (1) · Japan (1) · Mexico (1) · New Zealand (1) · Poland (1) · Romania (1) · Singapore (1) · South Korea (1)
Anastasia Becker (1) · Colleen Annesley (1) · Colleen Annesley, MD (1) · Corinne Summers (1) · Corinne Summers, MD (1) · Dionisios Vrochides, MD PhD (1) · James Pingpank, MD (1) · Salma Jabbour, MD (1) · Tannaz Armaghany, MD (1)
2018 (1), R01CA104524 (1)